Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153

Benzinga Newsdesk www.benzinga.com Positive 84.1%

Neg 0% Neu 0% Pos 84.1%

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $151 to $153.